Endodiabesity

The North West of England Endocrinology, Diabetes and Obesity Newsletter

Canagliflozin and Cardiovascular and Renal Events: NEJM

Posted by Akheel Syed on 21 August, 2017

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

In two trials involving patients with type 2 diabetes and an elevated risk of cardiovascular disease, patients treated with canagliflozin had a lower risk of cardiovascular events than those who received placebo but a greater risk of amputation, primarily at the level of the toe or metatarsal.

doi:10.1056/NEJMoa1611925

 

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s